Search

Author/Creator Peguero, Julio

1. 790 A phase II study (TACTI-002) of eftilagimod alpha (a soluble LAG-3 protein) with pembrolizumab in PD-L1 unselected patients with metastatic non-small cell lung(NSCLC) or head and neck carcinoma(HNSCC). (10th December 2020)

Authors:
Krebs, Matthew; Majem, Margarita; Felip, Enriqueta; Forster, Martin; Doger, Bernard; Clay, Tim; Carcereny, Enric; Peguero, Julio; Horn, Leora; Bajaj, Pawan; Roxburgh, Patricia; Brignone, Chrystelle; Mueller, Christian; Triebel, Frederic
Journal:
Journal for immunotherapy of cancer
Issue:
Volume 8(2020)Supplement 3
Page Start:
A472
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. 790 A phase II study (TACTI-002) of eftilagimod alpha (a soluble LAG-3 protein) with pembrolizumab in PD-L1 unselected patients with metastatic non-small cell lung(NSCLC) or head and neck carcinoma(HNSCC). (9th November 2020)

Authors:
Krebs, Matthew; Majem, Margarita; Felip, Enriqueta; Forster, Martin; Doger, Bernard; Clay, Tim; Carcereny, Enric; Peguero, Julio; Horn, Leora; Bajaj, Pawan; Roxburgh, Patricia; Brignone, Chrystelle; Mueller, Christian; Triebel, Frederic
Journal:
Journal for immunotherapy of cancer
Issue:
Volume 8(2020)Supplement 3
Page Start:
A839
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

3. Avelumab monotherapy as first-line or second-line treatment in patients with metastatic renal cell carcinoma: phase Ib results from the JAVELIN Solid Tumor trial. Issue 1 (24th October 2019)

Authors:
Vaishampayan, Ulka; Schöffski, Patrick; Ravaud, Alain; Borel, Christian; Peguero, Julio; Chaves, Jorge; Morris, John C.; Kotecki, Nuria; Smakal, Martin; Zhou, Dongli; Guenther, Silke; Bajars, Marcis; Gulley, James L.
Journal:
Journal for immunotherapy of cancer
Issue:
Volume 7:Issue 1(2019)
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

4. Eflapegrastim, a Long‐Acting Granulocyte‐Colony Stimulating Factor for the Management of Chemotherapy‐Induced Neutropenia: Results of a Phase III Trial. (16th June 2020)

Authors:
Schwartzberg, Lee S.; Bhat, Gajanan; Peguero, Julio; Agajanian, Richy; Bharadwaj, Jayaram S.; Restrepo, Alvaro; Hlalah, Osama; Mehmi, Inderjit; Chawla, Shanta; Hasal, Steven J.; Yang, Zane; Cobb, Patrick Wayne
Journal:
Oncologist
Issue:
Volume 25:Number 8(2020)
Page Start:
e1233
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗